Xenon Pharmaceuticals Inc.

XENE · Nasdaq · SIC 2834: Pharmaceutical Preparations
228
SEC Filings

Business Summary

We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. We are advancing a differentiated product pipeline led by our investigational candidate, azetukalner, which is being studied in multiple Phase 3 studies in epilepsy, major depressive disorder, or MDD, and bipolar depression, or BPD. Our early-stage pipeline includes Kv7 potassium channel openers and Nav sodium channel ...

Next Earnings

Q2 FY2026 — expected 2026-08-06

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionXENEdiscussed_in_filing Cybersecurity
topic_mentionXENEdiscussed_in_filing Cybersecurity
topic_mentionXENEdiscussed_in_filing Healthcare & Bio
topic_mentionXENEdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-262025-12-310001193125-26-076650EDGAR86K words
2025-02-272024-12-310000950170-25-029149EDGAR—
2024-02-292023-12-310000950170-24-023177EDGAR—
2023-03-012022-12-310000950170-23-005582EDGAR—
2022-03-012021-12-310001564590-22-008060EDGAR—
2021-03-012020-12-310001564590-21-009905EDGAR—
2020-03-092019-12-310001564590-20-009385EDGAR—
2019-03-062018-12-310001564590-19-006514EDGAR—
2018-03-072017-12-310001564590-18-004750EDGAR—
2017-03-082016-12-310001564590-17-003716EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-032025-09-300001193125-25-262646EDGAR49K words
2025-08-112025-06-300000950170-25-106599EDGAR—
2025-05-122025-03-310000950170-25-069342EDGAR—
2024-11-122024-09-300000950170-24-125547EDGAR—
2024-08-082024-06-300000950170-24-094109EDGAR—
2024-05-092024-03-310000950170-24-057139EDGAR—
2023-11-082023-09-300000950170-23-061200EDGAR—
2023-08-092023-06-300000950170-23-040681EDGAR—
2023-05-092023-03-310000950170-23-019775EDGAR—
2022-11-082022-09-300000950170-22-023283EDGAR—
2022-08-092022-06-300001564590-22-028780EDGAR—
2022-05-102022-03-310001564590-22-019318EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-130001193125-26-106144EDGAR1K words
2026-03-120001193125-26-104199EDGAR—
2026-03-090001193125-26-097577EDGAR—
2026-02-270001193125-26-082520EDGAR—
2026-02-260001193125-26-076530EDGAR—
2025-12-010001193125-25-303862EDGAR—
2025-11-030001193125-25-262519EDGAR—
2025-10-160001193125-25-241546EDGAR—
2025-08-110000950170-25-106529EDGAR—
2025-07-030000950170-25-093996EDGAR—

228 total filings indexed. 196 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001582313
TickerXENE
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedA1

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 0325ad3bf60064ae2f501410d066948f1d325bdff84894e3411d96459a30f06a
parent: b541467306d15197fc9df914f443ded8b3185fcc8a24f660db6d9addeeaba096
content hash: a3f8e30b9ca658d55fca93e662dcc2df3a7dd06c685ef7db109a89b38c232509
signed: 2026-04-13T04:48:17.748Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf